ABSTRACT
Amisulpride has been used to treat psychotic disorders and more recently even chronic fatigue. We describe 2 cases with somatoform disorders and who responded to low-dose amisulpride.
Subject(s)
Antipsychotic Agents/therapeutic use , Somatoform Disorders/drug therapy , Sulpiride/analogs & derivatives , Adult , Amisulpride , Fatigue Syndrome, Chronic/drug therapy , Female , Humans , Psychotic Disorders/drug therapy , Sulpiride/therapeutic use , Young AdultABSTRACT
A legal framework is essential to promote and safeguard the interests of persons with mental illness. Since the Indian Lunacy Act, 1912, mental health legislation has come a long way. Currently efforts are underway to modify the existing Mental Health Act taking into account the resolutions under the UN Convention on the Rights of Persons with Disabilities. The proposed Mental Health Care Bill, 2011 incorporates promising modifications, like "caregiver", "nominated representative", "consent", "support" for decision making, and "advance directive" for persons with mental illness in its rubric, which seems potentially beneficial to the patients. The proposed new bill should facilitate and strengthen a mental health policy which provides acceptable, accessible, and equitable mental health care. A law becomes meaningful when it is realistic, implementable and ethical in provisions. In this comment, we take a critical look at the proposed 'The Mental Health Care Bill, 2011' through the lens of ethical principles.
Subject(s)
Health Policy , Health Services Accessibility , Human Rights , Mental Health Services/ethics , Mental Health Services/legislation & jurisprudence , Public Health/legislation & jurisprudence , Advance Directives/ethics , Advance Directives/legislation & jurisprudence , Health Services Accessibility/ethics , Health Services Accessibility/legislation & jurisprudence , Human Rights/legislation & jurisprudence , Humans , India , Informed Consent/ethics , Informed Consent/legislation & jurisprudence , Public Health/ethicsSubject(s)
Somatoform Disorders/drug therapy , Sulpiride/analogs & derivatives , Adult , Amisulpride , Female , Humans , Male , Middle Aged , Sulpiride/therapeutic use , Treatment OutcomeABSTRACT
AIMS: To assess the change in salivary flow rate in patients with schizophrenia on clozapine and whether the change in salivary flow rate was dose related. METHODS: Twenty male inpatients with a diagnosis of schizophrenia according to the International Statistical Classification of Diseases, 10th Revision diagnostic criteria for research who were started on clozapine were recruited for the study. Unstimulated salivary flow rate was assessed at baseline and then weekly for 4 weeks using cotton swab method in 17 patients. RESULTS: Repeated-measures analysis of variance showed a significant increase in salivary flow rate over time (F [2.37/37.94] = 3.134, P = 0.047, Greenhouse-Geisser correction, eta = 0.16). Also, there was a significant increase in salivary flow rate between weeks 2 and 3 (P < 0.05). There was no correlation between salivary flow rate and mean clozapine dose. CONCLUSIONS: There was a significant increase in salivary flow rate from baseline after starting clozapine, with a significant increase from the second to the third week followed by a "plateau."
